WO2007071048A1 - Viable cells from frozen umbilical cord tissue - Google Patents
Viable cells from frozen umbilical cord tissue Download PDFInfo
- Publication number
- WO2007071048A1 WO2007071048A1 PCT/CA2006/002092 CA2006002092W WO2007071048A1 WO 2007071048 A1 WO2007071048 A1 WO 2007071048A1 CA 2006002092 W CA2006002092 W CA 2006002092W WO 2007071048 A1 WO2007071048 A1 WO 2007071048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- tissue
- umbilical cord
- cord tissue
- frozen
- Prior art date
Links
- 210000001519 tissues Anatomy 0.000 title claims abstract description 434
- 210000003954 Umbilical Cord Anatomy 0.000 title claims abstract description 184
- 210000000130 stem cell Anatomy 0.000 claims abstract description 148
- 235000015110 jellies Nutrition 0.000 claims abstract description 108
- 239000008274 jelly Substances 0.000 claims abstract description 108
- 210000004027 cells Anatomy 0.000 claims description 652
- 238000000034 method Methods 0.000 claims description 106
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 82
- 239000012091 fetal bovine serum Substances 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 54
- 238000007710 freezing Methods 0.000 claims description 52
- 238000003860 storage Methods 0.000 claims description 42
- 210000002966 Serum Anatomy 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 36
- 230000029087 digestion Effects 0.000 claims description 22
- 238000010257 thawing Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 210000004369 Blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 14
- 230000035899 viability Effects 0.000 claims description 14
- 238000007654 immersion Methods 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 210000004786 perivascular cells Anatomy 0.000 claims description 6
- 210000004204 Blood Vessels Anatomy 0.000 abstract description 4
- 239000002609 media Substances 0.000 description 110
- 210000000988 Bone and Bones Anatomy 0.000 description 56
- 239000002953 phosphate buffered saline Substances 0.000 description 56
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 56
- 230000001464 adherent Effects 0.000 description 42
- 239000000243 solution Substances 0.000 description 38
- 239000000284 extract Substances 0.000 description 36
- 102000020504 Collagenase family Human genes 0.000 description 34
- 108060005980 Collagenase family Proteins 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 34
- 229960002424 collagenase Drugs 0.000 description 34
- 238000005755 formation reaction Methods 0.000 description 32
- 230000004069 differentiation Effects 0.000 description 30
- 238000000605 extraction Methods 0.000 description 30
- 230000002188 osteogenic Effects 0.000 description 30
- 238000003306 harvesting Methods 0.000 description 28
- 239000011159 matrix material Substances 0.000 description 28
- 210000000981 Epithelium Anatomy 0.000 description 26
- 239000004793 Polystyrene Substances 0.000 description 26
- 229920002223 polystyrene Polymers 0.000 description 26
- 239000006228 supernatant Substances 0.000 description 26
- 239000000727 fraction Substances 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 24
- 229960002180 Tetracycline Drugs 0.000 description 22
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 22
- 239000004098 Tetracycline Substances 0.000 description 22
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 235000019364 tetracycline Nutrition 0.000 description 22
- 210000001789 adipocyte Anatomy 0.000 description 20
- 230000003115 biocidal Effects 0.000 description 20
- 229920001436 collagen Polymers 0.000 description 20
- -1 from 10-30% DMSO Chemical compound 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 18
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 18
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 18
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 210000002808 Connective Tissue Anatomy 0.000 description 18
- 229960003957 Dexamethasone Drugs 0.000 description 18
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 18
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 18
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 18
- 239000003242 anti bacterial agent Substances 0.000 description 18
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 18
- 239000000969 carrier Substances 0.000 description 18
- 229960005188 collagen Drugs 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 229940079866 intestinal antibiotics Drugs 0.000 description 18
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 18
- 238000011084 recovery Methods 0.000 description 18
- 206010054107 Nodule Diseases 0.000 description 16
- 230000002293 adipogenic Effects 0.000 description 16
- 238000005138 cryopreservation Methods 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 230000001114 myogenic Effects 0.000 description 16
- 230000002792 vascular Effects 0.000 description 16
- 210000000845 Cartilage Anatomy 0.000 description 14
- 210000004700 Fetal Blood Anatomy 0.000 description 14
- 102000004965 antibodies Human genes 0.000 description 14
- 108090001123 antibodies Proteins 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 210000003205 Muscles Anatomy 0.000 description 12
- 210000002950 fibroblast Anatomy 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000001000 micrograph Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 102100000789 DES Human genes 0.000 description 10
- 108010044052 Desmin Proteins 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000002648 chondrogenic Effects 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 238000001878 scanning electron micrograph Methods 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 8
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 8
- 210000001612 Chondrocytes Anatomy 0.000 description 8
- 102100005499 PTPRC Human genes 0.000 description 8
- 101700059076 PTPRC Proteins 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 239000004698 Polyethylene (PE) Substances 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 229960003942 amphotericin B Drugs 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007172 antigens Proteins 0.000 description 8
- 102000038129 antigens Human genes 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000002224 dissection Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 239000011713 pantothenic acid Substances 0.000 description 8
- 238000005057 refrigeration Methods 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000011099 tissue engineering Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 8
- 210000002805 Bone Matrix Anatomy 0.000 description 6
- 210000002351 Embryonic Muscle Cell Anatomy 0.000 description 6
- 210000002889 Endothelial Cells Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 6
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 6
- 108060008487 Myosin family Proteins 0.000 description 6
- 102000003505 Myosin family Human genes 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000013127 Vimentin Human genes 0.000 description 6
- 108010065472 Vimentin Proteins 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 210000002449 bone cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001086 cytosolic Effects 0.000 description 6
- 210000002919 epithelial cells Anatomy 0.000 description 6
- 230000001605 fetal Effects 0.000 description 6
- 239000000834 fixative Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000001963 growth media Substances 0.000 description 6
- 230000003394 haemopoietic Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000002055 immunohistochemical Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 101700016479 myo3 Proteins 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 229940014662 pantothenate Drugs 0.000 description 6
- 235000019161 pantothenic acid Nutrition 0.000 description 6
- 210000003668 pericytes Anatomy 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002062 proliferating Effects 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 230000017423 tissue regeneration Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 229960001322 trypsin Drugs 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3-Isobutyl-1-methyl-2,6(1H,3H)-purinedione Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010043137 Actomyosin Proteins 0.000 description 4
- KDXHLJMVLXJXCW-UHFFFAOYSA-J Alcian blue stain Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cu+2].[N-]1C(N=C2C3=CC(CSC(N(C)C)=[N+](C)C)=CC=C3C(N=C3C4=CC=C(CSC(N(C)C)=[N+](C)C)C=C4C(=N4)[N-]3)=N2)=C(C=C(CSC(N(C)C)=[N+](C)C)C=C2)C2=C1N=C1C2=CC(CSC(N(C)C)=[N+](C)C)=CC=C2C4=N1 KDXHLJMVLXJXCW-UHFFFAOYSA-J 0.000 description 4
- 208000003432 Bone Disease Diseases 0.000 description 4
- 210000001185 Bone Marrow Anatomy 0.000 description 4
- IXIBAKNTJSCKJM-BUBXBXGNSA-N Bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 4
- 229920002574 CR-39 Polymers 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000003038 Endothelium Anatomy 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 210000003743 Erythrocytes Anatomy 0.000 description 4
- 210000002744 Extracellular Matrix Anatomy 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102100005905 MYF5 Human genes 0.000 description 4
- 101700000140 MYF5 Proteins 0.000 description 4
- 102100018549 MYOG Human genes 0.000 description 4
- 101700014819 MYOG Proteins 0.000 description 4
- 108020004999 Messenger RNA Proteins 0.000 description 4
- 230000036740 Metabolism Effects 0.000 description 4
- 108010056785 Myogenin Proteins 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- 102100000077 PPARG Human genes 0.000 description 4
- 229940049954 Penicillin Drugs 0.000 description 4
- 229940056360 Penicillin G Drugs 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 210000003324 RBC Anatomy 0.000 description 4
- 229960005322 Streptomycin Drugs 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 210000003934 Vacuoles Anatomy 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 229960000626 benzylpenicillin Drugs 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000011072 cell harvest Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001413 cellular Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 230000035611 feeding Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229920002106 messenger RNA Polymers 0.000 description 4
- 230000035786 metabolism Effects 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 210000000663 muscle cells Anatomy 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 230000000790 osteoblast Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000003442 weekly Effects 0.000 description 4
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-Aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 101710026064 ACTA2 Proteins 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 101700078950 CD44 Proteins 0.000 description 2
- 102100003735 CD44 Human genes 0.000 description 2
- 210000002791 CFU-M Anatomy 0.000 description 2
- 229960004015 Calcitonin Drugs 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 235000000638 D-biotin Nutrition 0.000 description 2
- 239000011665 D-biotin Substances 0.000 description 2
- 108009000133 Differentiation Pathway Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 101710004932 ECU01_0460 Proteins 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 241000272184 Falconiformes Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 210000001654 Germ Layers Anatomy 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000001974 Hyaluronidase Human genes 0.000 description 2
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N Nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 210000004409 Osteocytes Anatomy 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 102100002458 TGFB3 Human genes 0.000 description 2
- 101700026084 THY1 Proteins 0.000 description 2
- 210000001138 Tears Anatomy 0.000 description 2
- 210000002435 Tendons Anatomy 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 210000003606 Umbilical Veins Anatomy 0.000 description 2
- 210000001325 Yolk Sac Anatomy 0.000 description 2
- 210000002945 adventitial reticular cell Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000735 allogeneic Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 230000034127 bone morphogenesis Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001332 colony forming Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 230000001082 cryoprotectant Effects 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000000254 damaging Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001079 digestive Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000003511 endothelial Effects 0.000 description 2
- 230000032686 female pregnancy Effects 0.000 description 2
- 230000003328 fibroblastic Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010952 in-situ formation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 230000002045 lasting Effects 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000651 myofibroblasts Anatomy 0.000 description 2
- 230000004070 myogenic differentiation Effects 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 210000001316 polygonal cell Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/158,616 US8278102B2 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
AU2006329195A AU2006329195B2 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
EP06840519.0A EP1976980B1 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
JP2008546056A JP2009520466A (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
BRPI0621107-0A BRPI0621107A2 (en) | 2005-12-22 | 2006-12-21 | viable cell retrieval method of umbilical cord tissue, preservation of viability of cells present in umbilical cord tissue, umbilical cord tissue and viable hucpvcs recovery method |
KR1020087017748A KR101507172B1 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
CA2634820A CA2634820C (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
KR1020147032981A KR20140146220A (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
IL192311A IL192311A (en) | 2005-12-22 | 2008-06-19 | Viable cells from frozen umbilical cord tissue and methods of obtaining same |
US13/630,480 US8790923B2 (en) | 2005-12-22 | 2012-09-28 | Viable cells from frozen umbilical cord tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75298905P | 2005-12-22 | 2005-12-22 | |
US60/752,989 | 2005-12-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/158,616 A-371-Of-International US8278102B2 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
US13/630,480 Continuation US8790923B2 (en) | 2005-12-22 | 2012-09-28 | Viable cells from frozen umbilical cord tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007071048A1 true WO2007071048A1 (en) | 2007-06-28 |
Family
ID=38188226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2006/002092 WO2007071048A1 (en) | 2005-12-22 | 2006-12-21 | Viable cells from frozen umbilical cord tissue |
Country Status (11)
Country | Link |
---|---|
US (2) | US8278102B2 (en) |
EP (1) | EP1976980B1 (en) |
JP (3) | JP2009520466A (en) |
KR (2) | KR20140146220A (en) |
CN (2) | CN103173401A (en) |
AU (1) | AU2006329195B2 (en) |
BR (1) | BRPI0621107A2 (en) |
CA (1) | CA2634820C (en) |
IL (1) | IL192311A (en) |
SG (1) | SG10201401805YA (en) |
WO (1) | WO2007071048A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021333A1 (en) * | 2007-08-14 | 2009-02-19 | Tissue Regeneration Therapeutics Inc. | Blood vessel extraction from umbilical cord |
US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
EP2288359A1 (en) * | 2008-04-21 | 2011-03-02 | Tissue Regeneration Therapeutics Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
CN102600509A (en) * | 2011-01-25 | 2012-07-25 | 上海交通大学医学院附属第九人民医院 | Osteoblast derived from cryopreserved bone, and application of osteoblast derived from cryopreserved bone in bone tissue regeneration |
US8278102B2 (en) | 2005-12-22 | 2012-10-02 | Jane Ennis | Viable cells from frozen umbilical cord tissue |
US8277794B2 (en) | 2006-05-05 | 2012-10-02 | Davies John E | Immune privileged and modulatory progenitor cells |
CN102960334A (en) * | 2011-09-01 | 2013-03-13 | 生宝生物科技股份有限公司 | Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells |
US8481311B2 (en) | 2003-02-11 | 2013-07-09 | Tissue Regeneration Therapeutics Inc. | Progenitor cells from wharton's jelly of human umbilical cord |
US8691217B2 (en) | 2005-12-29 | 2014-04-08 | Anthrogenesis Corporation | Placental stem cell populations |
US8895256B2 (en) | 2005-10-13 | 2014-11-25 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8916146B2 (en) | 2007-02-12 | 2014-12-23 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
US9198938B2 (en) | 2008-11-19 | 2015-12-01 | Antrhogenesis Corporation | Amnion derived adherent cells |
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
US20160066566A1 (en) * | 2014-09-10 | 2016-03-10 | Healthbanks Biotech Co., Ltd. | Cryopreservation of umbilical cord tissue strips for cord tissue-derived stem cells |
US9339520B2 (en) | 2006-10-23 | 2016-05-17 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US10272119B2 (en) | 2005-09-27 | 2019-04-30 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US10342831B2 (en) | 2015-05-20 | 2019-07-09 | Tissuetech, Inc. | Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
US10426731B2 (en) | 2011-06-10 | 2019-10-01 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
US10925903B2 (en) | 2007-09-13 | 2021-02-23 | Reprobiogen Inc. | Use of cells derived from first trimester umbilical cord tissue |
US11116800B2 (en) | 2014-06-03 | 2021-09-14 | Tissuetech, Inc. | Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
US11365395B2 (en) | 2003-05-01 | 2022-06-21 | Lifenet Health | In vitro growth of tissues suitable to the formation of bone and bone forming tissue formed thereby |
US11590265B2 (en) | 2015-02-23 | 2023-02-28 | Biotissue Holdings Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
US11707492B2 (en) | 2016-01-29 | 2023-07-25 | Biotissue Holdings Inc. | Fetal support tissue products and methods of use |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744597B2 (en) | 2002-06-26 | 2010-06-29 | Lifenet Health | Device and process for producing fiber products and fiber products produced thereby |
US8796315B2 (en) | 2009-06-25 | 2014-08-05 | Darlene E. McCord | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
JP2012031127A (en) * | 2010-08-03 | 2012-02-16 | Nagoya Univ | Composition including umbilical cord matrix stromal cell |
CN101922048B (en) * | 2010-08-06 | 2014-12-31 | 青岛奥克生物开发有限公司 | Method for constructing public library of umbilical mesenchymal stem cells |
US8932805B1 (en) * | 2011-10-31 | 2015-01-13 | BioDlogics, LLC | Birth tissue material and method of preparation |
EP2775928B1 (en) | 2011-11-08 | 2019-02-20 | Auxocell Laboratories Inc. | Systems and methods for processing cells |
US9670457B2 (en) * | 2012-05-08 | 2017-06-06 | Stem Cell Reserve Lp | Stem cells and matrix from cord tissue |
CA2892375A1 (en) | 2012-11-30 | 2014-06-05 | Darlene E. MCCORD | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
CN105163704B (en) * | 2013-02-22 | 2019-07-26 | 莱福奈特海尔斯公司 | For storing the package component of tissue and cell material |
JP6745449B2 (en) * | 2013-12-27 | 2020-08-26 | ゼノアックリソース株式会社 | Umbilical cord tissue cryopreservation method |
US10400211B1 (en) | 2014-04-28 | 2019-09-03 | Donnie Rudd | Cell composition for tissue regeneration |
US9993748B2 (en) | 2014-08-11 | 2018-06-12 | Auxocell Laboratories, Inc. | Centrifuge clip and method |
USD748462S1 (en) | 2014-08-11 | 2016-02-02 | Auxocell Laboratories, Inc. | Centrifuge clip |
GB2532499A (en) * | 2014-11-21 | 2016-05-25 | Virgin Health Bank Qstp-Llc | Improvements in tissue processing |
CA2980316A1 (en) | 2015-03-24 | 2016-09-29 | Osiris Therapeutics, Inc. | Compositions comprising meniscal tissues and uses thereof |
US11122796B1 (en) | 2016-02-19 | 2021-09-21 | Regents Of The University Of Minnesota | Cryoprotection compositions and methods |
CN105766890B (en) * | 2016-02-26 | 2018-05-22 | 生宝生物科技股份有限公司 | The Cord blood of umbilical cord tissue and the method for obtaining its derived stem cells |
WO2017184721A1 (en) | 2016-04-19 | 2017-10-26 | Regents Of The University Of Minnesota | Cryopreservation compositions and methods involving nanowarming |
JP6756155B2 (en) | 2016-05-26 | 2020-09-16 | 住友電気工業株式会社 | Resin composition for flat cable reinforcing tape and flat cable |
KR102015502B1 (en) * | 2018-03-29 | 2019-08-28 | 아키소스템바이오스트래티지스(주) | A method for the isolation of stem cells from human umbilical cords |
WO2020033959A1 (en) * | 2018-08-10 | 2020-02-13 | Predictive Technology Group, Inc. | Cryopreservation medium for umbilical cord mscs derived from wharton's jelly |
WO2020150529A1 (en) * | 2019-01-17 | 2020-07-23 | Regents Of The University Of Minnesota | System and method for cryopreservation of tissues |
WO2021022377A1 (en) * | 2019-08-08 | 2021-02-11 | Tissue Regeneration Therapeutics Inc. | Perivascular lysates and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009521A1 (en) | 1989-12-22 | 1991-07-11 | Cryo-Cell International, Inc. | Identification process and related method for use in preparing a biological sample |
US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
WO2002086104A1 (en) | 2001-04-24 | 2002-10-31 | Dolores Baksh | Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
US20030161818A1 (en) * | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
WO2004072273A1 (en) | 2003-02-11 | 2004-08-26 | Davies John E | Progenitor cells from wharton's jelly of human umbilical cord |
WO2005027633A2 (en) * | 2003-09-16 | 2005-03-31 | 21St Century Medicine, Inc. | Methods and compositions for the cryopreservation of organs |
WO2005038012A2 (en) * | 2003-06-27 | 2005-04-28 | Ethicon Incorporated | Cartilage and bone repair and regeneration using postpartum-derived cells |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5158867A (en) * | 1987-08-21 | 1992-10-27 | Cryolife Inc. | Method for cryopreserving blood vessels |
US5891617A (en) * | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
US5897987A (en) * | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
US7670628B2 (en) | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
US20050158289A1 (en) | 1999-07-07 | 2005-07-21 | Simmons Paul J. | Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals |
AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
CA2381292C (en) | 1999-08-05 | 2016-05-24 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
GB0029847D0 (en) * | 2000-12-07 | 2001-01-24 | Univ Bristol | Preparation of spheroids |
US7736892B2 (en) * | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
JP2003267471A (en) * | 2002-03-15 | 2003-09-25 | Nipro Corp | Protecting external packaging bag for container for freezing and storing living tissue |
CA2521826C (en) | 2003-04-11 | 2013-08-06 | Jennifer L. Reed | Recombinant il-9 antibodies and uses thereof |
CA2529718C (en) | 2003-06-27 | 2012-10-23 | Universite Laval | Method of isolating cells from umbilical cord |
WO2005095583A1 (en) | 2004-03-03 | 2005-10-13 | Life-Sciences Ag | Large scale storage of viable somatic stem and/or progenitor cells |
DK1725656T3 (en) | 2004-03-05 | 2014-01-13 | John E Davies | Serum-free suspension culture system for mesenchymal progenitor cells |
MXPA06014577A (en) * | 2004-06-14 | 2007-03-23 | Galapagos Nv | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases. |
CA2971062C (en) | 2004-08-16 | 2019-02-26 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
US20060073592A1 (en) * | 2004-10-06 | 2006-04-06 | Wendell Sun | Methods of storing tissue matrices |
CA2634820C (en) | 2005-12-22 | 2021-05-25 | Jane Ennis | Viable cells from frozen umbilical cord tissue |
WO2007099534A2 (en) | 2006-03-01 | 2007-09-07 | The Regenerative Medicine Institute | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same |
BE1016380A6 (en) | 2006-04-06 | 2006-09-05 | Life Sciences Ag | Cryogenic preservation of stem and progenitor cells in umbilical cord, used for treating e.g. disease, comprises freezing whole section of umbilical cord tissue |
JP5431146B2 (en) | 2006-05-05 | 2014-03-05 | デイビーズ,ジヨン・イー | Immunological tolerance and regulatory progenitor cells |
-
2006
- 2006-12-21 CA CA2634820A patent/CA2634820C/en active Active
- 2006-12-21 KR KR1020147032981A patent/KR20140146220A/en not_active Application Discontinuation
- 2006-12-21 CN CN2012104603865A patent/CN103173401A/en active Pending
- 2006-12-21 KR KR1020087017748A patent/KR101507172B1/en active IP Right Grant
- 2006-12-21 EP EP06840519.0A patent/EP1976980B1/en active Active
- 2006-12-21 WO PCT/CA2006/002092 patent/WO2007071048A1/en active Application Filing
- 2006-12-21 US US12/158,616 patent/US8278102B2/en active Active
- 2006-12-21 CN CNA2006800533137A patent/CN101479377A/en active Pending
- 2006-12-21 AU AU2006329195A patent/AU2006329195B2/en not_active Ceased
- 2006-12-21 BR BRPI0621107-0A patent/BRPI0621107A2/en not_active Application Discontinuation
- 2006-12-21 SG SG10201401805YA patent/SG10201401805YA/en unknown
- 2006-12-21 JP JP2008546056A patent/JP2009520466A/en not_active Withdrawn
-
2008
- 2008-06-19 IL IL192311A patent/IL192311A/en not_active IP Right Cessation
-
2012
- 2012-09-28 US US13/630,480 patent/US8790923B2/en active Active
-
2013
- 2013-04-12 JP JP2013083995A patent/JP2013172721A/en not_active Withdrawn
-
2015
- 2015-09-03 JP JP2015173621A patent/JP2016105702A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009521A1 (en) | 1989-12-22 | 1991-07-11 | Cryo-Cell International, Inc. | Identification process and related method for use in preparing a biological sample |
US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
WO2002086104A1 (en) | 2001-04-24 | 2002-10-31 | Dolores Baksh | Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
US20030161818A1 (en) * | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
WO2004072273A1 (en) | 2003-02-11 | 2004-08-26 | Davies John E | Progenitor cells from wharton's jelly of human umbilical cord |
US20050148074A1 (en) | 2003-02-11 | 2005-07-07 | Davies John E. | Progenitor cells from wharton's jelly of human umbilical cord |
WO2005038012A2 (en) * | 2003-06-27 | 2005-04-28 | Ethicon Incorporated | Cartilage and bone repair and regeneration using postpartum-derived cells |
WO2005027633A2 (en) * | 2003-09-16 | 2005-03-31 | 21St Century Medicine, Inc. | Methods and compositions for the cryopreservation of organs |
Non-Patent Citations (25)
Title |
---|
AUBIN,JE, BONE STEM CELLS: J CELL BIOCHEM, vol. 30-31, 1998, pages 73 - 82 |
CAPLAN,AI, MESENCHYMAL STEM CELLS: J ORTHOP.RES, vol. 9, 1991, pages 641 - 650 |
CARLIN R. ET AL.: "Expression of early transcription factors Oct-4, Sox-2, and Nanog by porcine umbilical cord (PUC) matrix cells", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, vol. 4, no. 8, February 2006 (2006-02-01), pages 1 - 13, XP021018829 * |
CHACKO,AW; S R M REYNOLDS: "Contributions to Embryology", vol. 35, 1954, article "Architecture of deistended and nondistended human umbilical cord tissues, with special reference to the arteries and veins.: Carnegie Institution of Washington", pages: 135 - 150 |
CONGET,P; J J MINGUELL: "Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells", J.CELL PHYSIOL, vol. 181, 1999, pages 67 - 73, XP002967649, DOI: doi:10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO;2-C |
HAYNESWORTH,SE; D REUBEN; A I CAPLAN: "Cell-based tissue engineering therapies: the influence of whole body physiology", ADV DRUG DELIV REV, vol. 33, 1998, pages 3 - 14, XP001154414, DOI: doi:10.1016/S0169-409X(98)00016-7 |
HORWITZ EM; PROCKOP DJ; FITZPATRICK LA; KOO WW; GORDON PL; NEEL M ET AL.: "Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta", NAT MED, vol. 5, 1999, pages 309 - 313, XP002924802, DOI: doi:10.1038/6529 |
JE DAVIES: "Bone Engineering", 2000, EM SQUARED, INC., article CANFIELD,AE; M J DOHERTY; B A ASHTON: "Osteogenic potential of vascular pericytes", pages: 143 - 151 |
KOGLER,G; S SENSKEN; J A AIREY; T TRAPP; M MUSCHEN; N FELDHAHN; S LIEDTKE; R V SORG; J FISCHER; C ROSENBAUM: "A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential", J EXP.MED., vol. 200, 2004, pages 123 - 135 |
MA L. ET AL.: "Human umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiation into nerve-like cells", CHINESE MEDICAL JOURNAL, vol. 118, no. 23, 5 December 2005 (2005-12-05), pages 1987 - 1993, XP008084144 * |
MITCHELL,KE; M L WEISS; B M MITCHELL; P MARTIN; D DAVIS; L MORALES; B HELWIG; M BEERENSTRAUCH; K ABOU-EASA; T HILDRETH: "Matrix cells from Wharton's jelly form neurons and glia", STEM CELLS, vol. 21, 2003, pages 50 - 60, XP002281007 |
NAUGHTON B.A. ET AL.: "Cells isolated from Wharton's jelly of the human umbilical cord develop a cartilage phenotype when treated with TGFbeta in vitro", FASEB JOURNAL, vol. 11, no. 3, 1997, pages A19, XP002059521 * |
PARRY,EW: "Some electron microscope observations on the mesenchymal structures of full-term umbilical cord", JOURNAL OF ANATOMY, vol. 107, 1970, pages 505 - 518 |
PEREDA,J; P M MOTTA: "New advances in human embryology: morpho functional relationship between the embryo and the yolk sac", MEDICAL ELECTRON MICROSCOPY, vol. 32, 2002, pages 67 - 78 |
ROMANOV,YA; V A SVINTSITSKAYA; V N SMIRNOV: "Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord", STEM CELLS, vol. 21, 2003, pages 105 - 110, XP002331940, DOI: doi:10.1634/stemcells.21-1-105 |
SARUGASER R. ET AL.: "Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors", STEM CELLS, vol. 23, no. 2, February 2005 (2005-02-01), pages 220 - 229, XP003015847 * |
SCHOENBERG,MD; A HINMAN; R D MOORE: "Studies on connective tissue V, Feber formation in Wharton's Jelly", LABORATORY INVESTIGATION, vol. 9, 1960, pages 350 - 355 |
See also references of EP1976980A4 |
SEN,A; Y R LEA-CURRIE; D SUJKOWSKA; D M FRANKLIN; W O WILKISON; Y D HALVORSEN; J M GIMBLE: "Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous", J.CELL BIOCHEM., vol. 81, 2001, pages 312 - 319 |
TAKECHI,K; Y KUWABARA; M MIZUNO: "Ultrastructural and immunohistochemical studies of Wharton's jelly umbilical cord cells", PLACENTA, vol. 14, 1993, pages 235 - 245, XP055260265, DOI: doi:10.1016/S0143-4004(05)80264-4 |
THOMAS WHARTON, ADENOGRAPHIA |
TUCHMANN-DUPLESSIS,H; G DAVID; P HAEGEL: "Illustrated Human Embryology", 1972, SPRINGER-VERLAG, pages: 54 - 61 |
WEISS,L: "Histology: cell and tissue biology", 1983, ELSEIVER BIOMEDICAL, pages: 997 - 998 |
WHARTON TW: "Adenographia", vol. 1656, 1996, OXFORD UNIVERSITY PRESS, pages: 242 - 248 |
WHARTON,TW: "Adenographia", 1996, OXFORD UNIVERSITY PRESS, pages: 242 - 248 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
US9611456B2 (en) | 2003-02-11 | 2017-04-04 | Tissue Regeneration Therapeutics Inc. | Progenitor cells from wharton'S jelly of human umbilical cord |
US9567564B2 (en) | 2003-02-11 | 2017-02-14 | Tissue Regeneration Therapeutics Inc. | Progenitor cells from Wharton's jelly of human umbilical cord |
US8481311B2 (en) | 2003-02-11 | 2013-07-09 | Tissue Regeneration Therapeutics Inc. | Progenitor cells from wharton's jelly of human umbilical cord |
US11365395B2 (en) | 2003-05-01 | 2022-06-21 | Lifenet Health | In vitro growth of tissues suitable to the formation of bone and bone forming tissue formed thereby |
US10272119B2 (en) | 2005-09-27 | 2019-04-30 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US10632155B2 (en) | 2005-09-27 | 2020-04-28 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
US9539288B2 (en) | 2005-10-13 | 2017-01-10 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8895256B2 (en) | 2005-10-13 | 2014-11-25 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8278102B2 (en) | 2005-12-22 | 2012-10-02 | Jane Ennis | Viable cells from frozen umbilical cord tissue |
US8790923B2 (en) | 2005-12-22 | 2014-07-29 | Jane E. Ennis | Viable cells from frozen umbilical cord tissue |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
US8691217B2 (en) | 2005-12-29 | 2014-04-08 | Anthrogenesis Corporation | Placental stem cell populations |
US10383897B2 (en) | 2005-12-29 | 2019-08-20 | Celularity, Inc. | Placental stem cell populations |
US8277794B2 (en) | 2006-05-05 | 2012-10-02 | Davies John E | Immune privileged and modulatory progenitor cells |
US8900573B2 (en) | 2006-05-05 | 2014-12-02 | John E. Davies | Immune privileged and modulatory progenitor cells |
US10105399B2 (en) | 2006-10-23 | 2018-10-23 | Celularity, Inc. | Methods and compositions for treatment of bone defects with placental cell populations |
US9339520B2 (en) | 2006-10-23 | 2016-05-17 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US8916146B2 (en) | 2007-02-12 | 2014-12-23 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
WO2009021333A1 (en) * | 2007-08-14 | 2009-02-19 | Tissue Regeneration Therapeutics Inc. | Blood vessel extraction from umbilical cord |
US10925903B2 (en) | 2007-09-13 | 2021-02-23 | Reprobiogen Inc. | Use of cells derived from first trimester umbilical cord tissue |
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
AU2009240738B2 (en) * | 2008-04-21 | 2014-09-11 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
EP2288359A1 (en) * | 2008-04-21 | 2011-03-02 | Tissue Regeneration Therapeutics Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US9498544B2 (en) | 2008-04-21 | 2016-11-22 | Tissue Regeneration Therapeutics Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US9005599B2 (en) | 2008-04-21 | 2015-04-14 | Tissue Regeneration Therapeutics Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
EP2288359A4 (en) * | 2008-04-21 | 2012-12-26 | Tissue Regeneration Therapeutics Inc | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US9198938B2 (en) | 2008-11-19 | 2015-12-01 | Antrhogenesis Corporation | Amnion derived adherent cells |
US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
US9464274B2 (en) | 2010-07-13 | 2016-10-11 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
CN102600509A (en) * | 2011-01-25 | 2012-07-25 | 上海交通大学医学院附属第九人民医院 | Osteoblast derived from cryopreserved bone, and application of osteoblast derived from cryopreserved bone in bone tissue regeneration |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US11090339B2 (en) | 2011-06-01 | 2021-08-17 | Celularity Inc. | Treatment of pain using placental stem cells |
US10426731B2 (en) | 2011-06-10 | 2019-10-01 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
CN102960334A (en) * | 2011-09-01 | 2013-03-13 | 生宝生物科技股份有限公司 | Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US11116800B2 (en) | 2014-06-03 | 2021-09-14 | Tissuetech, Inc. | Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof |
US9913466B2 (en) * | 2014-09-10 | 2018-03-13 | Healthbanks Biotech Co. Ltd. | Cryopreservation of umbilical cord tissue strips for cord tissue-derived stem cells |
US20160066566A1 (en) * | 2014-09-10 | 2016-03-10 | Healthbanks Biotech Co., Ltd. | Cryopreservation of umbilical cord tissue strips for cord tissue-derived stem cells |
US11590265B2 (en) | 2015-02-23 | 2023-02-28 | Biotissue Holdings Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
US10342831B2 (en) | 2015-05-20 | 2019-07-09 | Tissuetech, Inc. | Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
US11318169B2 (en) | 2015-05-20 | 2022-05-03 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
US11707492B2 (en) | 2016-01-29 | 2023-07-25 | Biotissue Holdings Inc. | Fetal support tissue products and methods of use |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101507172B1 (en) | 2015-03-31 |
CA2634820C (en) | 2021-05-25 |
AU2006329195A1 (en) | 2007-06-28 |
AU2006329195B2 (en) | 2012-09-20 |
EP1976980B1 (en) | 2019-03-06 |
US20130023049A1 (en) | 2013-01-24 |
CA2634820A1 (en) | 2007-06-28 |
IL192311A0 (en) | 2008-12-29 |
JP2009520466A (en) | 2009-05-28 |
IL192311A (en) | 2012-06-28 |
US20090275127A1 (en) | 2009-11-05 |
JP2013172721A (en) | 2013-09-05 |
BRPI0621107A2 (en) | 2011-11-29 |
EP1976980A4 (en) | 2012-04-18 |
KR20140146220A (en) | 2014-12-24 |
SG10201401805YA (en) | 2014-08-28 |
CN101479377A (en) | 2009-07-08 |
KR20080081053A (en) | 2008-09-05 |
US8278102B2 (en) | 2012-10-02 |
US8790923B2 (en) | 2014-07-29 |
CN103173401A (en) | 2013-06-26 |
JP2016105702A (en) | 2016-06-16 |
EP1976980A1 (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8790923B2 (en) | Viable cells from frozen umbilical cord tissue | |
US9611456B2 (en) | Progenitor cells from wharton'S jelly of human umbilical cord | |
US20090068153A1 (en) | Cell composition for tissue regeneration | |
ENNIS et al. | Patent 2634820 Summary | |
AU2012227326B2 (en) | Progenitor cells from wharton's jelly of human umbilical cord |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680053313.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008546056 Country of ref document: JP Ref document number: 2634820 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006329195 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6288/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017748 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006840519 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006329195 Country of ref document: AU Date of ref document: 20061221 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006329195 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12158616 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0621107 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080620 |